|
|
The Clinical Efficacy of Lamotrigine Combined with Topiramate in the Treatment of Children with Epilepsy and its Impact on Cognitive Function and Neurotrophic Factor Levels in Patients |
CHEN Jing, YANG Juping, JIN Hongguang, et al |
The Second Hospital of Jiaozuo,Jiaozuo Henan 454000 |
|
|
Abstract 【Objective】To explore the clinical efficacy of lamotrigine combined with topiramate in the treatment of children with epilepsy and its impact on cognitive function and neurotrophic factor levels in patients.【Methods】A retrospective analysis was conducted on the clinical data of 56 children with epilepsy admitted to our hospital from February 2021 to December 2022. According to different treatment plans, the children were divided into a control group (treated with lamotrigine) and an observation group (treated with lamotrigine and topiramate), with 28 cases in each group. Two groups were compared in terms of clinical efficacy, electroencephalogram efficacy, pre-treatment and post-treatment seizure status, neurokine levels [neuropeptide Y (NPY), insulin-like growth factor-1 (IGF-1), brain-derived neurotrophic factor (BDNF), intercellular adhesion molecule-1 (ICAM-1)], cognitive function [Wechsler Intelligence Scale (WISC-Ⅳ) score], anxiety and depression [Hamilton Anxiety Scale (HAMA) and Depression Scale (HAMD) score].【Results】The clinical effective rate and total effective rate of EEG in the observation group were higher than those in the control group, and the difference was statistically significant (P<0.05). After treatment, the frequency and duration of seizures in both groups were lower than before treatment, and the observation group was lower than the control group, with a statistically significant difference (P<0.05). After treatment, the WISC-Ⅳ score of the observation group was higher than that of the control group, and the HAMA and HAMD scores were lower than those of the control group (P<0.05). After treatment, the serum levels of NPY, IGF-1, BDNF, and ICAM-1 in both groups were lower than before treatment, and the observation group was lower than the control group, with statistical significance (P<0.05). 【Conclusion】The combination of lamotrigine and topiramate has a good clinical efficacy in the treatment of pediatric epilepsy, which can reduce the number of seizures, promote neurological function recovery, improve cognitive function, and alleviate anxiety and depression.
|
Received: 12 June 2023
|
|
|
|
|
[1] 潘靓,王君霞,余思逊,等.癫痫性猝死在儿童中的研究进展[J].西南国防医药,2021,31(1):59-62. [2] SPECCHIO N,WIRRELL E C,SCHEFFER I E, et al. International League Against Epilepsy classification and definition of epilepsy syndromes with onset in childhood: Position paper by the ILAE task force on nosology and definitions[J].Epilepsia,2022,63(6):1398-1442. [3] 吴盈盈,曹立,钟平.癫痫相关认知功能障碍的机制与评估[J].安徽医药,2023,27(4):637-640. [4] 杨理明,陈波,宁泽淑. 拉莫三嗪添加治疗对难治性癫痫患儿血清IL-2、TNF-α及认知功能的影响[J].医学临床研究,2014,31(11):2212-2214. [5] 杨理明,康庆云,江志.托吡酯对癫痫患儿血清瘦素、骨钙蛋白及血钙的影响[J].医学临床研究,2014,31(12):2404-2405. [6] 赵婧,王宁.四种抗癫痫药物对部分性癫痫患者认知功能及生活质量的影响对照研究[J].神经损伤与功能重建,2022,17(7):416-419. [7] 陶玉瑛,李惟滔,赵明明,等.儿童癫痫患者托吡酯群体药动学模型外部验证[J].中国药学杂志,2021,56(12):1020-1026. [8] 陈悦,张丽霞,张行,等.癫痫患儿拉莫三嗪联合托吡酯治疗效果及脑电图变化分析[J].中国病案,2020,21(12):109-112. [9] 薛韬,赵世刚,曹志,等.托吡酯联合拉莫三嗪对癫痫患者认知功能和生活质量的影响[J].现代生物医学进展,2020,20(3):515-518. [10] 梁稀,许虹,李欣潞,等.抑郁和焦虑情绪在癫痫患者客观认知功能和主观记忆间的中介作用[J].中华行为医学与脑科学杂志,2021,30(10):898-903. [11] 张金来,曹月荣,于洁,等.维生素E辅助拉莫三嗪治疗癫痫患儿的临床效果及对血清神经肽Y、胰岛素样生长因子-1、脑源性神经营养因子和S100B蛋白水平的影响[J].广西医学,2020,42(16):2076-2079. [12] RIIKONEN R, KOKKI H.CSF nerve growth factor (β-NGF) is increased but CSF insulin-like growth factor-(IGF-1) is normal in children with tuberous sclerosis and infantile spasms[J].Eur J Paediatr Neurol,2019,23(1):191-196. [13] WANG P,NAN S J,ZHANG Y Z, et al. Effects of GABAB receptor positive allosteric modulator BHF177 and IRS-1 on apoptosis of hippocampal neurons in rats with refractory epilepsy via the PI3K/Akt pathway[J].Cell Biol Int,2022,46(11):1775-1786. [14] 张俊华,于明,祁英杰,等.醒脑静注射液联合丙戊酸钠治疗脑卒中后癫痫疗效观察[J].新乡医学院学报,2020,37(9):852-855. [15] 杜双霞,张晓红,赵合意,等.miRNA-146a-5p对癫痫大鼠海马神经元NF-κB信号转导通路的影响[J].临床和实验医学杂志,2019,18(4):341-346. |
[1] |
. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 768-770. |
|
|
|
|